ツムラ（4540） – The Third Quarter of the Term Ending March 31, 2022 Supplementary Materials

TSE.4540Supplementary MaterialsThe Third Quarter of the Term Ending March 31, 2022February 4, 2022TSUMURA & CO.Consolidated Statements of Income ・・・・・ 1Capital investments, R&D expenses, etc. ・・・・・ 1Growth rates of 129 prescription Kampo products ・・・・・ 1・・・・・ 2Product salesConsolidated Balance Sheets・・・・・ 3Consolidated Statements of Cash Flows ・・・・・ 3Quarterly data　Consolidated Statements of Income ・・・・・ 4　Consolidated Balance Sheets ・・・・・ 4　Consolidated Statements of Cash Flows ・・・・・ 5・・・・・ 5　Product sales※The 2020 results have been rearranged to the amount after applying the PPA adjustment and new accoutingConsolidated Statements of Income(Million yen)FY 3/2021 3QcumulativeFY 3/2022 3QcumulativeYear-on-yearFull-year forecast for FY 3/2022Amount% of salesAmount% of salesAmount%Amount% of salesYear-on-yearYear-on-year(Amount)(%)100.0% 11,086 Net salesDomesticOverseasCost of salesGross profit on salesSelling, general and administrative expensesOperating profitOrdinary profitProfit attributable to owners of parent88,44484,5793,86441,69346,75029,51417,23517,81113,226100.0%95.6%4.4%47.1%52.9%33.4%19.5%20.1%15.0%98,38291,3177,06547,99750,38431,55418,82921,07415,389100.0%92.8%7.2%48.8%51.2%32.1%19.1%21.4%15.6%9,9386,7373,2006,3043,6342,0401,5933,2622,16211.2%8.0%82.8%15.1%7.8%6.9%9.2%18.3%16.4%127,500117,8009,70061,60065,90044,80021,10023,40016,60092.4% 7.6% 48.3% 51.7% 35.1% 16.5% 18.4% 13.0% 7,746 3,339 5,650 5,435 3,718 1,717 2,533 1,267 9.5% 7.0% 52.5% 10.1% 9.0% 9.1% 8.9% 12.1% 8.3% (Million yen)Capital investments, R&D expenses, etc.FY 3/2021 3QcumulativeFY 3/2022 3QcumulativeYear-on-yearFull-year forecast for FY 3/2022Amount% of salesAmount% of salesAmount%Amount% of salesYear-on-yearYear-on-year(Amount)(%)Capital investmentsR&D expensesAdvertising costDepreciation8,3864,8863535,9759.5%5.5%0.4%6.8%6,7165,1934816,4976.8%5.3%0.5%6.6%Personnel expenses23,74126.8%24,14524.5%(1,670)(19.9)%14,00011.0% 2,838 306 127 521 404 6.3% 36.0% 8.7% 1.7% 7,3001,0008,5005.7% 0.8% 6.7% 32,70025.6% 668 170 289 405 25.4% 10.1% 20.5% 3.5% 1.3% Growth rates of 129 prescription Kampo productsFY 3/2015FY 3/2016FY 3/2017FY 3/2018FY 3/2019FY 3/2020FY 3/2021FY 3/2022FY 3/2022FY 3/20221Q2Q3QAmountNumber of items with higher yen sales812.4% 2.3% 681.9% 952.4% 632.7% 831.8% 661.1% 827.8% 937.7% 1047.6% 1061Product salesRankNo.Product Name1234567891023☆ 100 Daikenchuto☆ 54YokukansanG41 Hochuekkito☆ 43 RikkunshitoGGG17 Goreisan24 Kamishoyosan68Shakuyakukanzoto☆ 107 Goshajinkigan114 SaireitoG29 Bakumondoto☆ 14 HangeshashintoTotal of “Drug Fostering” Program formulationsTotal of Growing formulationsTotal of 129 prescription Kampo products☆：”Drug Fostering” Program formulationsG ：Growing formulations2FY 3/2021FY 3/20223Q3QYear-on-year(Amount)(Million yen)Year-on-year(%)7,1255,4015,3285,1683,4263,3503,5212,4792,3872,41797321,14818,04481,1277,3345,6785,6555,5484,1113,7523,6922,6872,5592,4551,05222,30119,66687,293209 276 327 380 684 401 171 207 171 37 79 1,153 1,622 6,166 2.9% 5.1% 6.1% 7.4% 20.0% 12.0% 4.9% 8.4% 7.2% 1.6% 8.1% 5.5% 9.0% 7.6% Consolidated Balance Sheets(Million yen)As of March 31As of December 31,Increase /20212021decreaseTotal assetsCurrent assetsLiquid assetsInventoriesNon-current assetsProperty, plant and equipmentTotal liabilitiesCurrent liabilitiesNon-current liabilitiesTotal net assetsConsolidated Statements of Cash FlowsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at the end of the quarter319,063 204,273 109,934 80,755 114,789 84,176 85,894 48,380 37,513 338,432 221,541 121,193 87,217 116,890 86,548 88,946 41,986 46,960 233,169 249,485 FY 3/2021FY 3/20223Q3Q12,706 (4,975)(9,708)59,051 17,815 (7,510)(5,192)67,070 319,368 17,268 11,258 6,462 2,100 2,371 3,052 (6,394)9,446 16,316 5,108 (2,534)4,515 8,019 (Million yen)Year-on-yearQuarterly dataConsolidated Statements of IncomeNet salesDomesticOverseasCost of salesGross profit on salesSelling, general and administrative expensesOperating profitOrdinary profitProfit attributable to owners of parentConsolidated Balance SheetsTotal assetsCurrent assetsLiquid assetsInventoriesNon-current assetsProperty, plant and equipmentTotal liabilitiesCurrent liabilitiesNon-current liabilitiesTotal net assets(Million yen)cumulativeFY 3/2021FY 3/20222Q3Q4Q2Q3Q4Q1Q28,39627,41398213,45714,9389,2815,6575,6744,016cumulative56,95254,4752,47626,83030,12219,20210,92010,9098,002cumulative88,44484,5793,86441,69346,75029,51417,23517,81113,226cumulative116,413110,0536,36055,94960,46441,08119,38220,86615,3321Q31,77129,5132,25715,29816,47310,3216,1527,2475,389cumulative63,41658,8294,58730,72132,69521,01111,68413,4099,965cumulative98,38291,3177,06547,99750,38431,55418,82921,07415,389The end ofThe end ofThe end ofThe end ofThe endThe end ofThe end ofThe end ofFY 3/2021FY 3/2022(Million yen)4Q1Q313,521203,613113,94277,516109,90880,433100,26850,95349,314213,2532Q309,132197,445109,83775,178111,68782,48184,49044,49539,995224,6413Q313,505201,594110,56377,495111,91083,56985,35644,99540,361228,14844Q319,063204,273109,93480,755114,78984,17685,89448,38037,513233,169of326,956211,038112,77584,471115,91885,15387,01750,03436,983239,9382Q335,881218,576119,17487,104117,30486,56190,24043,82446,416245,6403Q338,432221,541121,19387,217116,89086,54888,94641,98646,960249,485No. / Product Name2Q3Q4Q2Q3Q4QConsolidated Statements of Cash FlowsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at the end of the quarterProduct sales100 Daikenchuto54 Yokukansan43 Rikkunshito107 Goshajinkigan14 Hangeshashinto41 Hochuekkito68 Shakuyakukanzoto29 Bakumondoto24 Kamishoyosan17 GoreisanTotal of “Drug Fostering” Program formulationsTotal of Growing formulationsTotal of “Drug Fostering” Programformulations and Growing formulationsTotal of 129 prescription Kampo products(Million yen)cumulative(Million yen)cumulativeFY 3/2021FY 3/20222Q3Q4Q2Q3Q4Q1Q5,503 1,214 (1,810)65,375 cumulative10,733 (2,539)(7,206)61,407 cumulative12,706 (4,975)(9,708)59,051 cumulative16,102 (7,352)(10,425)59,668 1Q3,360 (3,101)(2,371)59,278 cumulative11,815 (3,600)(2,733)67,296 cumulative17,815(7,510)(5,192)67,070FY 3/2021FY 3/20221Q2,3851,7791,6658203136,9651,7661,1318121,0421,0325,785cumulative4,6633,5423,3601,61063313,8103,5432,3101,4682,1502,24911,722cumulative7,1255,4015,1682,47997321,1485,3283,5212,4173,3503,42618,044cumulative9,2517,0176,6763,2291,25727,4326,7934,5243,1274,3364,41323,1961Q2,4301,8721,7708883457,3081,8181,2018061,2051,2976,330cumulative4,7903,7203,5571,73667814,4823,7412,4261,5312,4152,68012,794cumulative7,3345,6785,5482,6871,05222,3015,6553,6922,4553,7524,11119,66612,75025,53339,19250,62813,63827,27741,96826,33252,34381,127105,56728,37756,37787,2935